NEXALIN TECHNOLOGY INC (NXL)
US65345B2016 - Common Stock
NEXALIN TECHNOLOGY INC
NASDAQ:NXL (4/19/2024, 7:07:36 PM)
After market: 1.43 0 (0%)1.43
-0.04 (-2.72%)
Company Profile
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Laguna Niguel, California and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device, Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. The company is also designing clinical trials for the use of Gen-2 for the treatment of substance use disorders and particularly substance abuse issues related to opiates, chronic pain, Alzheimer’s disease and dementia. The firm's products are non-invasive and undetectable and can provide relief to those afflicted with mental health issues without adverse side effects. Its design of varying voltages, currents, electromagnetic fields and various frequencies called as waveform. The Company’s devices generate a high frequency, charge balanced electrical current waveform that is applied to an array of electrodes on the head.
Company Info
NEXALIN TECHNOLOGY INC
26072 Merit Circle, Suite 106
Laguna Niguel CALIFORNIA
P: 19492608090
Employees: 6
Website: https://nexalin.com
NXL News
a day ago - ChartmillWhat's going on in today's pre-market sessionFriday's pre-market session: top gainers and losers
4 days ago - ChartmillTuesday's session: top gainers and losersWondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
4 days ago - ChartmillHere are the top movers in Tuesday's session, showcasing the stocks with significant price changes.Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model...
11 days ago - Nexalin Technology, Inc.Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing16 days ago - Nexalin Technology, Inc.Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceNew method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes
NXL Twits
Here you can normally see the latest stock twits on NXL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
